Tags : Cell Therapies

GSK Signs a Five Years Collaboration with Lyell to Develop

Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion while increasing probability for delivering cancer therapies The focus of the agreement is to combine the GSK’s strong cell and gene therapy programmes with Lyell’s […]Read More

Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Shots: BlueRock to get $240M in cash as upfront and $360M as development milestones. In 2016, Bayer and Versant Ventures formed a joint venture establishing BlueRock Therapeutics, Bayer currently holds the 40.8% stock in BlueRock and will acquire the remaining stocks with its anticipated closure of transaction in Q3’19 The focus of the acquisition is […]Read More